Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo - Lexicon Pharmaceuticals (NASDAQ:LXRX)

THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport

Related Keywords

Ann Arbor ,Michigan ,United States ,Colorado ,Georgia ,Atlanta ,New York ,Texas ,Massachusetts ,Livia Stanger ,Lisa Defrancesco ,Craig Granowitz ,Alina Cocuzza ,Mario Enrico Canonico ,Preston Mason ,Rahul Aggarwal ,University Of Colorado ,Icahn School Of Medicine At Mount Sinai ,Drug Administration ,Clinical Research ,University Of Michigan ,American College Of Cardiology ,Large Us Integrated Health Systems ,Lexicon Pharmaceuticals ,Exchange Commission ,Lexicon Pharmaceuticals Inc ,Elucida Research ,American College ,Annual Scientific Session ,Reduces Stroke Outcomes ,Chronic Kidney Disease ,Icahn School ,Mount Sinai ,Modulated Expression ,Glucose Transport ,Inflammatory Proteins ,Endothelial Cells ,Inhibits Clotting Potential ,Platelet Activation ,Integrin Activation ,Human Platelets ,Heart Failure Medications Prescribed ,Hospitalized Patients According ,Two Large ,Health Systems ,Concomitant Use ,Insulin Secretagogues ,Mycotic Infections ,Glucose Test ,Adverse Reactions ,Specific Populations ,Investor Inquiries ,Media Inquiries ,